Recent challenges around preparing, transporting, and administering COVID-19 vaccines have received national and international attention. As part of our ongoing COVID-19 response, the U.S Pharmacopeia (USP) rapidly engaged stakeholders and convened experts to identify and help address operational efficiency gaps to help increase COVID-19 vaccinations.
FREDERICK, Md – January 26, 2021 – Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for VLX-1005 for the treatment of heparin induced thrombocytopenia (HIT).
“We are pleased the FDA has granted Orphan Drug Designation for VLX-1005 for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia,” said Jeffrey W. Strovel, PhD., Chief Executive Officer of Veralox Therapeutics. “This is a significant regulatory milestone for our company, and in the development of this investigational new drug product and recognition of the clear unmet medical need for patients who suffer from this devastating disease.” “
Amy Adams with George Mason University. Nikki Hastings with CvilleBioHub, and John Newby with Virginia Bio join Rich Bendis to discuss the new “Virginia Bio-Connect” statewide consortium and scale-Up initiative.
Listen now via Apple http://apple.co/39ZDl0M, Google http://bit.ly/3iRzmHO, Spotify https://spoti.fi/2MqHTVJ, and TuneIn http://bit.ly/2Yelr58. #innovation #biotalk #university #healthcare #digitalhealth #healthtech #research #biotech
EDA is pleased to announce today that seven organizations from across the United States have been awarded a total of $2 million in grants through the inaugural STEM Talent Challenge, which aims to boost local science, technology, engineering, and math (STEM) talent.
Grant projects are building STEM workforce readiness while fueling innovation and entrepreneurship in emerging and transformative sectors, such as space commerce, aeronautics, digital manufacturing, biotechnology, advanced manufacturing, and cybersecurity. Click here for more about each project.
For too long, the face of skincare has reflected only SOME of the faces we see within our communities. We know there are a lack of consumer products available tailored to the needs of the Black community.
As the world’s largest healthcare company, Johnson & Johnson recognizes and embraces our responsibility for enacting change. Within our consumer business, our products must reach, have a positive impact on, and most importantly, serve everyone. Looking to the future of healthcare, we must seek out and support innovators from diverse backgrounds in order to generate inclusive solutions.
The company, which is developing cancer treatments, plans to trade on the Nasdaq Global Market.
The number of changes being implemented by the new administration in the White House are likely too many to count. And while many are significant, one strikes a chord with the scientific community in a very meaningful way. In the days leading up to his inauguration, President Biden made it clear that science is a priority. He has backed that up with several recent announcements.
Alexandria LaunchLabs™ in Maryland, will provide fully equipped, affordable laboratory/office space with flexible lease terms, supporting infrastructure, access to amenities, and supporting services and programming through the project’s consortium of world-class partners, including Alexandria Venture Investments, BioHealth Innovation, Montgomery County, and the City of Gaithersburg. This unique, startup environment will accelerate the growth of local early-stage life science companies.
A nonprofit is considering Montgomery County as the site of a global pandemic center that would focus on prevention, research and response.
The Global Pandemic Prevention and Biodefense Center would serve as the “world’s epicenter” for pandemic prevention and biodefense ecosystem coordination.
County Council Member Hans Riemer proposed a $500,000 special appropriation to help fund the strategy phase of the project, which began in December. The appropriation was introduced at the council’s meeting on Tuesday.
GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters’ option. The offering is expected to close on January 26, 2021, subject to customary closing conditions.
